In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical ...

The US’s policy under the Second Donald Trump Administration has undergone major changes, with experts saying that America is ...

There's no reason the U.S. can't pick up the pace to match the global clinical research front-runners without compromising ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

Home-grown start-up Mirxes is going places, but co-founder is firmly rooted in Singapore. Read more at straitstimes.com. Read ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

The Chinese government claimed in 2021 that more than 80% of cotton harvesting was done by machine. But people are still ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

China is now setting the pace in life sciences R&D, conducting more clinical trials than the U.S. and licensing new ...

Swiss biotechnology companies are stepping up expansion and investments in China, eyeing its huge market potential and improved policies to accommodate foreign capital, said executives and ...